Navigation Links
MicroRNA controls malignancy and resistance of breast cancer cells
Date:5/4/2012

Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.

"Resistances to drugs are the main reason why therapies fail and disease progresses in many cancers," Wiemann explains. "We want to understand what goes on in the cells when this happens so we can develop better therapies in the future." Wiemann's co-worker, Dr. zgr Sahin, suspects that tiny pieces of RNA known as microRNAs play a role in resistance development. "These minuscule RNA snippets control many cellular processes by attaching themselves to target gene transcripts and thus repressing protein production."

By treating breast cancer cells in vitro with regular doses of tamoxifen, Sahin's team induced resistance of these cells to the drug. As resistance developed, the cancer cells switched to the development program that makes them grow even more invasively and more malignantly. Checking the complete spectrum of microRNAs in the resistant tumor cells, the investigators noticed that production of microRNA 375 was more strongly reduced than others. When they boosted the production of microRNA 375, the cells started responding again to tamoxifen and switched back to their normal growth program. "This strongly suggests that a lack of microRNA 375 both increases malignancy and contributes to resistance development," says zgr Sahin.

If microRNA 375 levels are low, breast cancer cells increase the production of metadherin. Apparently, microRNA 375 suppresses the production of this cancer-promoting protein in healthy cells. In patients receiving tamoxifen therapy the team found that high metadherin levels in the cancer cells go along with a high risk of recurrence. This suggests that microRNA 375 and metadherin are involved in the development of resistance to tamoxifen.

"The analysis of microRNAs in breast cancer has put us on the track of metadherin. We will possibly be able to specifically influence the cancer-promoting properties of this protein in the future," says Wiemann describing the goal of further research.


'/>"/>

Contact: Dr. Sibylle Kohlstaedt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. MicroRNAs grease the cells circadian clockwork
3. MicroRNAs help control HIV life cycle
4. MicroRNA in human saliva may help diagnose oral cancer
5. Scientists use microRNAs to track evolutionary history for first time
6. Penn biologists determine microRNA activity is suppressed in mouse ovum
7. Pitt researchers discover big role for microRNA in lethal lung fibrosis
8. MicroRNA network study implicates rewired interactions in cancer
9. Study of microRNA helps NIH scientists unlock secrets of immune cells
10. Red blood cells have a tiny but effective protector -- microRNA
11. Newly identified RNA sequence is key in microRNA processing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2016)... 2016 This BCC Research report provides an ... RNA Sequencing (RNA Seq) market for the years 2015, ... and reagents, data analysis, and services. Use ... RNA-Sequencing market such as RNA-Sequencing tools and reagents, RNA-Sequencing ... affecting each segment and forecast their market growth, future ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
(Date:3/2/2016)... 2, 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ... as a Service Market 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief Commercial ... Executive Director and one of the founding commercial leaders responsible for the commercialization ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, ... Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from ... and the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman has ... associate in the firm’s Intellectual Property practice group. , Clients turn to Cushman ... He has an electrical engineering and computer engineering background, and experience in the ...
(Date:4/26/2016)... ... 26, 2016 , ... Mr. Palmer created the RPO business for Ceridian and ... multi-year managed services contract in the U.S. intelligence community with The SI (a Lockheed ... John Younger, founder of Accolo. “We are growing and his experience guiding our ...
Breaking Biology Technology: